Bone News and Research

RSS

ICREA researcher has set up spin-off Supragen at IRB Barcelona

Roger Gomis, ICREA researcher at the Institute of Research in Biomedicine (IRB Barcelona) has set up the spin-off Supragen. With the support of IRB Barcelona and the Instituci- Catalana de Recerca i Estudis Avan-ats (ICREA), this initiative is the second biotech company to emerge from the institute since June and the third since this centre was set up towards the end of 2005.

4 Oct 2011

More than three-quarters of cancer patients have vitamin D deficiency

More than three-quarters of cancer patients have insufficient levels of vitamin D (25-hydroxy-vitamin D) and the lowest levels are associated with more advanced cancer, according to a study presented on October 2, 2011, at the 53rd Annual Meeting of the American Society for Radiation Oncology.

4 Oct 2011

MR-guided focused ultrasound may effectively control essential tremor

In a presentation at the Congress of Neurological Surgeons today, University of Virginia neurosurgeon W. Jeffrey Elias, MD reported that preliminary results of a pilot clinical trial indicate that MR-guided focused ultrasound has the potential to safely and effectively control essential tremor (ET), a common neurological condition that affects 10 million Americans.

4 Oct 2011

Study: Fair-skinned people may need to take vitamin D supplements

Fair-skinned people who burn quickly in the sun may need to take supplements to ensure they get the right amount of vitamin D, new research finds.

4 Oct 2011

Sangamo's SB-509 fails to meet key endpoints in Phase 2b study for diabetic neuropathy

Sangamo BioSciences, Inc. today announced that its Phase 2b study (SB-509-901) did not meet its primary or secondary clinical endpoints in subjects with moderate severity diabetic neuropathy (DN) as compared to placebo.

3 Oct 2011

Potential new drug could treat mixed-lineage leukaemia

A team lead by Cancer Research UK scientists have shown that a potential new drug could treat mixed-lineage leukaemia (MLL), the most common form of leukaemia in babies, according to a study published in Nature today.

3 Oct 2011

Vexim obtains registration certificate for SpineJack in India

Vexim, the Med-Tech specialist in the minimally invasive, anatomical treatment of vertebral compression fractures, today announced that it has obtained the registration certificate for SpineJack in India.

3 Oct 2011

New research uses Tilman model to study metastasis of prostate cells into bone

The invasion of a new species into an established ecosystem can be directly compared to the steps involved in cancer metastasis. New research published in BioMed Central's open access journal Theoretical Biology and Medical Modelling uses the Tilman model of competition between invasive species to study the metastasis of prostate cells into bone.

3 Oct 2011

Less toxic amounts of chemotherapy medicine slows tumor growth: Scientists

University of Georgia scientists have found that smaller, less toxic amounts of chemotherapy medicine given frequently to mice with human prostate cancer noticeably slowed tumor growth.

1 Oct 2011

Kimmel Cancer Center at Jefferson celebrates two decades of caring and collaboration to beat cancer

From October forward, the Kimmel Cancer Center at Jefferson (KCC), a National Cancer Institute-designated cancer center, is celebrating 20 years of service to the community and the groundbreaking cancer research from the scientists and physicians who've provided an invaluable contribution to medical science and healthcare.

30 Sep 2011

G-Zero receives NIAID's Phase II Small Business Innovation Research Grant

G-Zero Therapeutics, an RTP company started in 2008 based on technologies from the University of North Carolina at Chapel Hill, has been awarded a $3 million Phase II Small Business Innovation Research Grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

30 Sep 2011

Oral steroid users twice as likely to have severe vitamin D deficiency

People taking oral steroids are twice as likely as the general population to have severe vitamin D deficiency, according to a study of more than 31,000 children and adults by scientists at Albert Einstein College of Medicine of Yeshiva University.

30 Sep 2011

Bone and joint health supplements market to be worth over $9 billion by 2017

A globally ageing population, changing consumer lifestyles and a focus on preventative medicine is driving growth in the bone and joint health supplements market, which is forecast to be worth over $9 billion by 2017.

29 Sep 2011

Researchers use patient's own stem cells to correct genetic alteration that causes SCD

Using a patient's own stem cells, researchers at Johns Hopkins have corrected the genetic alteration that causes sickle cell disease (SCD), a painful, disabling inherited blood disorder that affects mostly African-Americans. The corrected stem cells were coaxed into immature red blood cells in a test tube that then turned on a normal version of the gene.

29 Sep 2011

Simple low-cost method for isolation and collection of fragile prostate cancer cells

At the Oct. 2-6 microTAS 2011 conference, the premier international event for reporting research in microfluidics, nanotechnology and detection technologies for life science and chemistry, University of Cincinnati researchers will present a simple, low-cost, method for separating and safely collecting concentrated volumes of fragile prostate cancer cells.

29 Sep 2011

SanBio initiates SB623 Phase 1/2a clinical trial in ischemic stroke

SanBio, Inc. has announced that a patient at Stanford University Medical Center has become the first to be treated with SB623, a novel cell therapy for patients with disability resulting from ischemic stroke.

29 Sep 2011

DJO receives exclusive rights to sell Exos' range of upper extremity products

DJO Global, Inc., a leading global provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced that it has signed an exclusive distribution agreement with Exos Corporation, providing DJO with exclusive rights to sell Exos' broad range of upper extremity products that incorporate Exos' thermoformable polymer technology in North and South America.

28 Sep 2011